Allurion Technologies shares rose after agreeing to a private placement with expected gross proceeds of $2.5 million that will extend its runway through early 2026. The stock was up 13% to $3.37 ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...

However, as noted by Dr Nik Ritza Kosai, an increasing number of people are now opting for an innovative, non-invasive treatment, namely the swallowable intragastric balloon (IGB ... Dr Nik Ritza ...

In Malaysia, cases of overweight and obesity are now increasing at an alarming rate. Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's ...

The study revealed that over half of the participants treated with the Allurion Balloon achieved significant weight loss at 48 weeks. The AUDACITY trial, which is the first FDA pivotal trial for an ...

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...